•  
  •  
  •  
  •  

2025-10-19 03:12:07

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Emirates NBD to acquire majority stake in RBL Bank through primary infusion of ~USD 3bn
  • PNGS Gargi Fashion Jewellery Ltd opens new store at Pajifond, Margao
  • Satchmo Holdings Ltd discharges its total liability as per OTS
  • Zenith Steel Pipes & Industries Ltd inks MoU with Lloyds Realty Developers Ltd to develop its land
  • Sejal Glass Ltd consolidated Q2 FY26 net profit rises to Rs. 8.02 crores

Keywords Selected:  Biotechnology

Research

  • Q2FY22 Result Update - Biocon Ltd - ICICI Direct

Stock Report

  • Biocon Biologics and Civica Expand Partnership and Launch Private-Label Insulin Glargine
  • Biocon Limited updates on GMP inspection by USFDA at its Cranbury, New Jersey facility
  • Panacea Biotec Ltd receives acceptance from CMSS for supply of bOPV
  • Biocon Pharma Ltd in partnership with Carnegie Pharmaceuticals LLC receives USFDA tentative approval for Rifaximin Tablets
  • Panacea Biotec Ltd receives LoA from UNICEF
  • Biocon Biologics Secures U.S. Market Entry Date for Bosaya™ and Aukelso™, Denosumab Biosimilars
  • Panacea Biotec Launches India's first 100% toxin-free and safe NikoMom Baby Skin Care
  • Biocon Inaugurates First U.S. Manufacturing Facility in Cranbury, New Jersey
  • U.S. FDA Completes Inspection at Biocon Biologics' Facility at Biocon Campus, Bengaluru, India
  • Vivo Bio Tech Ltd secures landmark Pre-Clinical Testing Contract Valued at ₹10.75 Crores
  • Biocon Foundation and IISc Commemorate World Head & Neck Cancer Day
  • Biocon Biologics Expands Diabetes Portfolio with FDA Approval of Kirsty™
  • Panacea Biotec Ltd updates on arbitration settlement with Apotex Inc
  • Biocon Biologics receives MHRA UK Approval for Vevzuo® and Evfraxy®, Denosumab Biosimilars
  • Biocon Biologics expands Insulin Access in Malaysia
  • Biocon Biologics Collaborates with National Cancer Society Malaysia
  • Biocon Limited gets approval for diabetes drug Liraglutide in India
  • Biocon Biologics and Yoshindo expand access to Ustekinumab Biosimilar in Japan
  • Biocon Biologics and Civica, Inc. collaborate to expand Insulin Aspart access in the United States
  • Biocon Limited launches its Glucagon-like peptide-1 (GLP -1), Liraglutide, in the United Kingdom
  • Biocon Biologics Receives MHRA, UK Approval for YESAFILI®, Biosimilar Aflibercept
  • Biocon Pharma Ltd receives ANDA approval for Mycophenolic Acid
  • Biocon Enters Prestigious Dow Jones Sustainability Emerging Markets Index
  • Biocon Biologics and Viatris announce Insulin Glargine Injection will be offered through the Walgreens Prescription Savings Club

Latest Post

  • Emirates NBD to acquire majority stake in RBL Bank through primary infusion of ~USD 3bn
  • PNGS Gargi Fashion Jewellery Ltd opens new store at Pajifond, Margao
  • Satchmo Holdings Ltd discharges its total liability as per OTS
  • Zenith Steel Pipes & Industries Ltd inks MoU with Lloyds Realty Developers Ltd to develop its land
  • Sejal Glass Ltd consolidated Q2 FY26 net profit rises to Rs. 8.02 crores


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2024